RPID Rapid Micro Biosystems Inc.

Medical Device Company
4.21
-0.01  0%
Previous Close 4.22
Open 4.38
52 Week Low 3.57
52 Week High 27.04
Market Cap $176,577,723
Shares 41,942,452
Float 24,149,653
Enterprise Value $22,774,147
Volume 72,007
Av. Daily Volume 243,201
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/11/2022

Latest News

  1. Reports first quarter 2022 commercial revenue of $4.2 million

    Reaffirms full year 2022 commercial revenue outlook range of $27 million to $32 million, representing growth of approximately 25% to 50%

    LOWELL, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2022.

    Recent Highlights

    • First quarter commercial revenue (combined product and service revenue) was $4.2 million
    • First quarter recurring commercial revenue was $2.7 million…
    View Full Article
  2. MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth.

    "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology.  "Having managed large, global biopharmaceutical and life sciences organizations over the course…

    View Full Article
View All Rapid Micro Biosystems Inc. News